Mind Medicine Inc
$ 12.95
-3.79%
30 Dec - close price
- Market Cap 1,308,570,000 USD
- Current Price $ 12.95
- High / Low $ 13.47 / 12.85
- Stock P/E N/A
- Book Value 1.70
- EPS -1.98
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -0.86 %
- 52 Week High 14.43
- 52 Week Low 4.70
About
Mind Medicine (MindMed) Inc. is a pioneering biotechnology company based in New York, specializing in psychedelic-inspired therapies for addiction and mental health disorders. The firm is at the forefront of developing evidence-based treatments through rigorous clinical trials and innovative research, aiming to address the increasing global mental health crisis. By integrating advanced psychedelics into therapeutic protocols, MindMed is strategically positioned as a leader in the expanding field of psychedelic medicine, making it an attractive opportunity for institutional investors seeking to engage with transformative advancements in healthcare.
Analyst Target Price
$28.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-07-31 | 2025-05-06 | 2025-02-26 | 2024-11-07 | 2024-08-13 | 2024-05-08 | 2024-02-28 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-09 |
| Reported EPS | -0.78 | -0.5 | -0.35 | -0.41 | -0.27 | -0.26 | -1.14 | -0.59 | -0.45 | -0.76 | -0.52 | -0.16 |
| Estimated EPS | -0.5 | -0.37 | -0.53 | -0.2786 | -0.28 | -0.33 | -0.53 | -0.46 | -0.67 | -0.54 | -0.42 | -0.5 |
| Surprise | -0.28 | -0.13 | 0.18 | -0.1314 | 0.01 | 0.07 | -0.61 | -0.13 | 0.22 | -0.22 | -0.1 | 0.34 |
| Surprise Percentage | -56% | -35.1351% | 33.9623% | -47.1644% | 3.5714% | 21.2121% | -115.0943% | -28.2609% | 32.8358% | -40.7407% | -23.8095% | 68% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.5233 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNMD
-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
2025-12-29 22:08:28
Mind Medicine (MindMed) insider Mark Sullivan sold 11,276 shares of the company's stock on December 26th at an average price of $13.15, totaling $148,279.40. This transaction reduced his position by 3.84% to 282,576 shares. Following the sale, MNMD stock traded up 3.1% to $13.46, though the company recently missed quarterly EPS estimates and analysts forecast a negative full-year EPS.
2025-12-26 07:09:22
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) has received an average "Buy" rating from twelve analysts, with an average 12-month price target of $30.33. The company, which focuses on psychedelic-inspired therapies, recently missed quarterly EPS estimates but institutional investors are increasing their stakes. Key programs include MM-120 for anxiety, MM-310 for addiction, and MM-402 for mood/stress.
2025-12-26 06:09:22
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) has received a consensus "Buy" rating from twelve analysts, with an average 12-month price target of $30.33. The clinical-stage biopharma company, which develops psychedelic-inspired therapies, reported quarterly EPS of ($0.78) against an expected ($0.52). Institutional investors own approximately 27.9% of the company's stock, with some increasing their stakes recently.
2025-12-25 18:09:08
Jones Trading initiated research on Mind Medicine (MindMed) with an optimistic view on its MM120 program for generalized anxiety disorder and major depressive disorder, seeing the company positioned well in psychedelic drug development. The firm also noted emerging New Jersey legislation supporting regulated therapeutic psilocybin access, suggesting favorable policy changes could impact MindMed positively. However, investors should be aware of the company's reliance on MM120, its current zero revenue, rising net losses, and relatively expensive balance sheet despite the recent equity raise.
2025-12-24 07:09:36
Jones Trading has initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy recommendation, according to a report from Fintel on December 23, 2025. Analysts project an 86.65% upside with an average one-year price target of $26.15/share. The article also details institutional ownership changes, highlighting a decrease in overall shares owned by institutions but some individual funds increasing their allocations.
2025-12-23 16:09:55
Mind Medicine (MindMed) (NASDAQ:MNMD) experienced a pre-market stock price gap up, opening at $13.65 after closing at $13.30 and trading near $13.95. The company's stock is trading above its 50-day and 200-day moving averages, and analysts generally have a bullish sentiment with a consensus target price of $30.33, despite the company remaining unprofitable. Insider selling was noted, reducing overall insider ownership in the company.
